Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBX-13
- Development stage
- Preclinical
- Lead developer
- Ibex Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
IBX-13 is a monoclonal antibody developed by Ibex Biosciences for the treatment of infectious diseases, with its primary indication being malaria. The drug is currently in preclinical development and has not yet entered clinical trials. There are references to an "IBX13 ADC," which suggests that an antibody-drug conjugate (ADC) version of this molecule may also be under investigation, particularly in oncology (digestive system neoplasms), but the canonical form "IBX-13" refers specifically to the monoclonal antibody for malaria[1][2][4]. The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025.
- Other names
- IBX13IBX-13IBX 13IBX-13 ADCIBX13 ADCIBX 13 ADC
Beyond the preview
Go deeper on IBX-13.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBX-13.